glp 1 agonist crohn's disease SAFETY AND CLINICAL EFFECTIVENESS OF GLP1 AGONISTS IN INFLAMMATORY BOWEL PATIENTS ADJUNCTIVE GLP-1 RECEPTOR AGONISTS IN
Description
Karwi QG, Biswas D, Pulinilkunnil T, Lopaschuk GD
Mol Metab 46, 101090 (2021)
Total weight loss by week 12 typically ranges from 5% to 8% of starting body weight, depending on the medication and dose
Hou Y, Dan X, Babbar M, Wei Y, Hasselbalch SG, Croteau DL, et al
They are more proactively involved in managing their condition and open to therapies that can help achieve optimal glucose control safely
Ozempic, on the other hand, has a well-established track record and a strong safety profile
